ES2176719T3 - Derivados de benzopirano que tienen una accion antagonista de leucotrienos. - Google Patents

Derivados de benzopirano que tienen una accion antagonista de leucotrienos.

Info

Publication number
ES2176719T3
ES2176719T3 ES97914280T ES97914280T ES2176719T3 ES 2176719 T3 ES2176719 T3 ES 2176719T3 ES 97914280 T ES97914280 T ES 97914280T ES 97914280 T ES97914280 T ES 97914280T ES 2176719 T3 ES2176719 T3 ES 2176719T3
Authority
ES
Spain
Prior art keywords
group
derivatives
methylene
benzopirano
leucotriens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97914280T
Other languages
English (en)
Inventor
Germano Carganico
Casellas David Mauleon
Avellana Jaime Pascual
Perez M Luisa Garcia
Benet Albert Palomer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Menarini SA
Original Assignee
Laboratorios Menarini SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Menarini SA filed Critical Laboratorios Menarini SA
Application granted granted Critical
Publication of ES2176719T3 publication Critical patent/ES2176719T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/54—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition of compounds containing doubly bound oxygen atoms, e.g. esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS DERIVADOS BENZOPIRANO DE FORMULA (I), DONDE A ES UN ATOMO DE OXIGENO O AZUFRE O UN GRUPO METILENO; B Y C SON: A) CUANDO B ES UN HETEROCICLO BENZOCONDENSADO (A) CUANDO U ES UN ATOMO DE O, S O N, Z - Y SON DOS ATOMOS DE CARBONO UNIDOS POR UN ENLACE SENCILLO O DOBLE; Y T ES UN ENLACE SENCILLO, UN GRUPO METILENO O CARBONILO; C PUEDE SER UN GRUPO - CONR 7 -, CSNR 7 -, - SO 2 NR 7 -, - CH 2 O -, O - CH = CH - ; B) CUANDO B ES UN GRUPO FENILO (B), C PUEDE SER UN GRUPO - SO 2 NR 7 -, - CH 2 O , O - CH = CH -; D ES UN GRUPO 5 - TETRAZOLILO O - COOR 8 , DONDE R 8 ES HIDROGENO, UN GRUPO ALQUILO O FENILALQUILO (C 1 - C 4 ); Y M Y N SON ENTEROS COMPRENDIDOS ENTRE 0 Y 4. DICHOS COMPUESTOS MUESTRAN UNA ACTIVIDAD ANTAGONISTA DE LEUCOTRIENO, Y SON VALIOSOS COMO MEDICAMENTOS ANTIALERGICOS Y ANTIINFLAMATORIOS, O PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES.
ES97914280T 1996-03-21 1997-03-20 Derivados de benzopirano que tienen una accion antagonista de leucotrienos. Expired - Lifetime ES2176719T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009600682A ES2127106B1 (es) 1996-03-21 1996-03-21 Derivados benzopiranicos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de los mismos.

Publications (1)

Publication Number Publication Date
ES2176719T3 true ES2176719T3 (es) 2002-12-01

Family

ID=8294261

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009600682A Expired - Lifetime ES2127106B1 (es) 1996-03-21 1996-03-21 Derivados benzopiranicos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de los mismos.
ES97914280T Expired - Lifetime ES2176719T3 (es) 1996-03-21 1997-03-20 Derivados de benzopirano que tienen una accion antagonista de leucotrienos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES009600682A Expired - Lifetime ES2127106B1 (es) 1996-03-21 1996-03-21 Derivados benzopiranicos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de los mismos.

Country Status (31)

Country Link
US (1) US5990142A (es)
EP (1) EP0888327B1 (es)
JP (1) JP3914575B2 (es)
KR (1) KR100378892B1 (es)
CN (1) CN1182129C (es)
AT (1) ATE219073T1 (es)
AU (1) AU707282B2 (es)
BG (1) BG63433B1 (es)
BR (1) BR9708215A (es)
CA (1) CA2249402C (es)
CU (1) CU22777A3 (es)
CZ (1) CZ296260B6 (es)
DE (1) DE69713300T2 (es)
DK (1) DK0888327T3 (es)
EA (1) EA001680B1 (es)
EE (1) EE03526B1 (es)
ES (2) ES2127106B1 (es)
GE (1) GEP20012416B (es)
HK (1) HK1018701A1 (es)
HU (1) HUP9901326A3 (es)
IL (1) IL126296A (es)
NO (1) NO319612B1 (es)
NZ (1) NZ331953A (es)
PL (1) PL189562B1 (es)
PT (1) PT888327E (es)
RS (1) RS49588B (es)
SI (1) SI0888327T1 (es)
SK (1) SK282979B6 (es)
TR (1) TR199801857T2 (es)
UA (1) UA65535C2 (es)
WO (1) WO1997034885A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE397672T1 (de) 1999-11-24 2008-06-15 Univ New York State Res Found Katalytische rnas mit aminoacylierender aktivität
CA2476425C (en) * 2002-02-15 2012-04-17 The Research Foundation Of State University Of New York At Buffalo Ribozymes with broad trna aminoacylation activity
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
US20050065099A1 (en) * 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
CN100475781C (zh) * 2004-02-13 2009-04-08 沃尼尔·朗伯有限责任公司 雄激素受体调节剂
AP2006003700A0 (en) 2004-02-13 2006-08-31 Warner Lambert Co Androgen receptor modulators
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
BRPI0513020A (pt) * 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
EP1781599A1 (en) * 2004-08-18 2007-05-09 Warner-Lambert Company LLC Androgen modulators
TW200724139A (en) * 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
US20090170886A1 (en) * 2005-08-08 2009-07-02 Pfizer Inc Androgen modulators
JP5119444B2 (ja) * 2005-12-06 2013-01-16 国立大学法人 東京大学 多目的アシル化触媒とその用途
ITMI20061606A1 (it) * 2006-08-09 2008-02-10 Dipharma Spa Procedimento per la preparazione di composti nitrilici
CN102304052A (zh) * 2011-07-28 2012-01-04 浙江大学 一种制备5-溴-2-羟基-3-硝基苯乙酮的方法
CN103980257B (zh) * 2014-05-28 2016-04-27 苏州开元民生科技股份有限公司 8-硝基-2-四氮唑基-4-羰基苯并吡喃的合成方法
CN104402711A (zh) * 2014-11-12 2015-03-11 平湖优康药物研发有限公司 一种抗哮喘药物普伦斯特中间体的合成工艺
CN113651788B (zh) * 2021-09-16 2023-11-21 东华理工大学 一种3-胺烷基色酮化合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977162A (en) * 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
JPH0395144A (ja) * 1989-08-04 1991-04-19 Ono Pharmaceut Co Ltd アミノフェノール誘導体の製造方法

Also Published As

Publication number Publication date
ES2127106B1 (es) 1999-11-16
CA2249402A1 (en) 1997-09-25
PL329027A1 (en) 1999-03-01
HUP9901326A3 (en) 2000-12-28
AU2158797A (en) 1997-10-10
US5990142A (en) 1999-11-23
GEP20012416B (en) 2001-04-25
SK282979B6 (sk) 2003-01-09
CN1214048A (zh) 1999-04-14
WO1997034885A1 (en) 1997-09-25
EP0888327B1 (en) 2002-06-12
HK1018701A1 (en) 1999-12-30
DE69713300T2 (de) 2002-09-26
CZ296260B6 (cs) 2006-02-15
DK0888327T3 (da) 2002-09-16
JP3914575B2 (ja) 2007-05-16
CA2249402C (en) 2006-10-24
EA001680B1 (ru) 2001-06-25
NO984330D0 (no) 1998-09-17
CN1182129C (zh) 2004-12-29
EE9800318A (et) 1999-04-15
PT888327E (pt) 2002-11-29
SI0888327T1 (en) 2002-10-31
SK127298A3 (en) 1999-03-12
DE69713300D1 (de) 2002-07-18
NZ331953A (en) 1999-03-29
ATE219073T1 (de) 2002-06-15
EA199800738A1 (ru) 1999-06-24
HUP9901326A2 (hu) 1999-08-30
TR199801857T2 (xx) 1998-12-21
CU22777A3 (es) 2002-07-24
BR9708215A (pt) 2000-01-04
KR20000064682A (ko) 2000-11-06
BG102775A (en) 1999-08-31
KR100378892B1 (ko) 2005-11-14
NO984330L (no) 1998-10-09
NO319612B1 (no) 2005-08-29
IL126296A (en) 2002-08-14
EP0888327A1 (en) 1999-01-07
ES2127106A1 (es) 1999-04-01
YU40798A (en) 1999-11-22
AU707282B2 (en) 1999-07-08
BG63433B1 (bg) 2002-01-31
JP2000506878A (ja) 2000-06-06
EE03526B1 (et) 2001-10-15
PL189562B1 (pl) 2005-08-31
UA65535C2 (en) 2004-04-15
IL126296A0 (en) 1999-05-09
RS49588B (sr) 2007-06-04
CZ299598A3 (cs) 1999-03-17

Similar Documents

Publication Publication Date Title
ES2176719T3 (es) Derivados de benzopirano que tienen una accion antagonista de leucotrienos.
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
ECSP066968A (es) Compuestos de metil-aril o heteroaril-amida sustituida
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
ES2112332T3 (es) Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico.
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
PE20010613A1 (es) Antagonistas de la hormona concentradora de la melanina
PE20000339A1 (es) Biciclo [2.2.1] heptanos y compuestos relacionados
PA8523001A1 (es) Derivados de la 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de glicogeno sintasa quinasa-3b
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
PE20030944A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
CO5650231A2 (es) Derivados de 1-(alquilaminoalquil-pirrolidin-/piperidinil)-2,2-difenilacetamida como antagonistas del receptor muscarinico, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
ES2196049T3 (es) Uso de 2-(2-alquilfenilamino)oxazolinas y -tiazolinas para la fabricacion de un medicamento con efecto alfa 2 adrenergico.
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
ATE243209T1 (de) Tetrahydro gamma-carboline
PE20040768A1 (es) Derivados de arilen-(2-amino-fenil)-carboxamida como inhibidores de la histona desacetilasa (hdac)
ES2063815T3 (es) 2-alquil-3-benzoilbenzofuranos y composiciones farmaceuticas que los contienen.
ATE245419T1 (de) Verwendung von benzofuroxanderivaten zur behandlung von angina pectoris